Rome, Italy

Maurizio Marta

This inventor holds 2 USPTO granted patents and 1 EPO patent. Top assignee: Consiglio Nazionale Delle Ricerche. Active years: 1989-1994.


% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 2

Forward Citations = 21(Granted Patents)


Company Filing History:


Years Active: 1989-1994

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Maurizio Marta: Innovator in Acetylcholinesterase Inhibition

Introduction

Maurizio Marta is a notable inventor based in Rome, Italy. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that inhibit acetylcholinesterase. His work has led to the filing of multiple patents, showcasing his innovative approach to medicinal chemistry.

Latest Patents

Maurizio Marta holds 2 patents related to Physostigmine derivatives with acetylcholinesterase inhibition properties. These patents describe compounds of general formula: ##STR1##, where R is a linear alkyl of from 2 to 20 carbon atoms, a branched alkyl, a cycloalkyl, or an aryl, when R' is H, or R and R' are linear alkyl of from 2 to 20 carbon atoms. These innovations are crucial for developing treatments for conditions affected by acetylcholine levels.

Career Highlights

Throughout his career, Maurizio Marta has worked with esteemed organizations, including the National Research Council of Italy (Consiglio Nazionale Delle Ricerche). His experience in research and development has positioned him as a key figure in his field.

Collaborations

Maurizio has collaborated with notable colleagues such as Alberto Oliverio and Flaminia Pavone. These partnerships have enhanced his research and contributed to the advancement of his innovative projects.

Conclusion

Maurizio Marta's contributions to the field of acetylcholinesterase inhibition highlight his role as an influential inventor. His patents and collaborations reflect his commitment to advancing medicinal chemistry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…